M&A news: Luye Pharma of China will pay $599 million to acquire a 58% stake in Beijing Jialin Pharmaceutical Co., a company that makes drug products for cardiovascular diseases and cancer.

In 2013, Jialin produced $185 million of revenue.

According to Luye, the m&a deal will add to its portfolio of cardiovascular drugs and broaden its sales network.

For further deal information visit Current Agreements (subscription required)

Related

Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Pharma and Biotech M&A Trends 2009-2014

Browse: Complete Current Partnering report catalog

View: Current Partnering’s M&A Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Partnering activity – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Parnering activity – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter